Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

@article{Harrington2004AntithromboticTF,
  title={Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.},
  author={Robert A. Harrington and Richard C. Becker and Michael D. Ezekowitz and Tom W Meade and Christopher M. O'connor and David A. Vorchheimer and Gordon H. Guyatt},
  journal={Chest},
  year={2004},
  volume={126 3 Suppl},
  pages={
          513S-548S
        }
}
This chapter about antithrombotic therapy for coronary artery disease (CAD) is part of the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence Based Guidelines. Grade 1 recommendations are strong and indicate that the benefits do, or do not, outweigh risks, burden, and costs. Grade 2 suggests that individual patients' values may lead to different choices (for a full understanding of the grading see Guyatt et al, CHEST 2004; 126:179S-187S). Among the key recommendations… 

Figures and Tables from this paper

Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
This chapter about prevention of coronary artery bypass occlusion is part of the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence Based Guidelines. Grade 1 recommendations
Anti-thrombotic therapy in non-ST elevation acute coronary syndrome ANTIPLATELET THERAPY Aspirin
  • Medicine
  • 2007
TLDR
This review will focus on non-ST elevation ACS, where clear evidence supports the use of both anti-platelet and anti-thrombin therapy.
Efficacy and safety of optimized antithrombotic therapy with aspirin, clopidogrel and enoxaparin in patients with non-ST segment elevation acute coronary syndromes in clinical practice
TLDR
In clinical practice optimized antithrombotic therapy with aspirin, clopidogrel and enoxaparin in NSTE-ACS is associated with a reduction in the combined endpoint of death and non-fatal reinfarctions compared to standard treatment with aspirin and UFH without increase in major bleeding complications.
Therapeutic approach in acute coronary syndrome focusing on oral therapy.
TLDR
Current therapeutic approach to patients with acute coronary syndrome especially focusing on oral therapy is being considered, and clopidogrel becomes an obligatory drug not only in patients having undergone PCI, but also in those treated conservatively following fibrinolysis.
Stroke, coronary and peripheral artery disease survey on antithrombotic treatment (START IT).
TLDR
Perception of primary care physicians regarding risk of subsequent atherothrombotic events varies in patients with CV disease, and as a result antithromBotic therapy is altered in Patients with anticipated high to very high risk even though robust evidence and clear guidelines are lacking.
Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction.
TLDR
It is proposed that, apart from low coronary risk situations, patients on antiplatelet drugs should continue their treatment throughout surgery, except when bleeding might occur in a closed space, and a therapeutic bridge with shorter-acting anti platelet drugs may be considered.
Safety of Clopidogrel and Aspirin for Stroke Prevention
TLDR
The results of the CHARISMA trial support this recommendation; despite previous data demonstrating a favourable benefit-risk profile of aspirin plus clopidogrel in patients with acute coronary syndrome, this combination should not be used in patients at high risk for atherothrombosis and those with previous stroke or TIA.
Novel antiplatelet agent ticagrelor in the management of acute coronary syndrome.
TLDR
A novel reversible and direct-acting oral adenosine diphosphate (ADP) receptor antagonist, ticagrelor was developed that showed consistent and increased P2Y12 inhibition with similar incidence of bleeding but greater reduction in cardiac events compared to clopidogrel.
...
...

References

SHOWING 1-10 OF 185 REFERENCES
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
TLDR
The antiplatelet agent clopidogrel has beneficial effects in patients with acute coronary syndromes without ST-segment elevation, however, the risk of major bleeding is increased among patients treated with clopIDogrel.
Clinical outcomes of bivalirudin for ischemic heart disease.
TLDR
Bivalirudin is at least as effective as heparin, with clearly superior safety, and provides an unprecedented net clinical benefit over hepar in patients with ischemic heart disease.
A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes.
  • M. Simoons
  • Medicine, Biology
    The New England journal of medicine
  • 1996
TLDR
Recombinant hirudin provided a small advantage, as compared with heparin, principally related to a reduction in the risk of nonfatal myocardial infarction and was not associated with a greater risk of major bleeding complications.
Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy.
TLDR
A meta-analysis of the randomized clinical trials of platelet glycoprotein IIb/IIIa inhibitor therapy in the medical management of non-ST-elevation acute coronary syndromes demonstrates an overall significant, albeit moderate, reduction in 30-day death or myocardial infarction associated with therapy.
Benefit of Glycoprotein IIb/IIIa Inhibition in Patients With Acute Coronary Syndromes and Troponin T–Positive Status: The PARAGON-B Troponin T Substudy
TLDR
Troponin T predicts poor short-term outcomes in non–ST-segment elevation ACS and treatment benefit with lamifiban is limited almost exclusively to TnT-positive patients, reducing 30-day adverse outcomes to a rate nearly identical to that of negative patients.
Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investigators.
TLDR
Eptifibatide reduced the composite rates of death or MI in PCI patients and those managed conservatively and this association disappeared after adjustment for propensity for early PCI.
Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group.
TLDR
In nonprior aspirin users, combination antithrombotic therapy with aspirin plus anticoagulation significantly reduces recurrent ischemic events in the early phase of unstable angina.
...
...